Leerink Partnrs Issues Optimistic Estimate for BSX Earnings

Boston Scientific Corporation (NYSE:BSX) – Research analysts at Leerink Partnrs lifted their FY2027 EPS estimates for shares of Boston Scientific in a report issued on Wednesday, October 1st. Leerink Partnrs analyst M. Kratky now forecasts that the medical equipment provider will earn $3.97 per share for the year, up from their prior estimate of $3.93. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific’s FY2028 earnings at $4.49 EPS and FY2029 earnings at $5.06 EPS.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the company posted $0.62 earnings per share. Boston Scientific’s revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS.

Other research analysts have also issued reports about the company. Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. UBS Group increased their target price on Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. BTIG Research raised their target price on Boston Scientific from $127.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a report on Saturday, September 27th. Finally, Raymond James Financial increased their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $120.79.

Boston Scientific Stock Performance

Shares of BSX stock opened at $97.30 on Friday. The company’s fifty day simple moving average is $102.93 and its 200-day simple moving average is $102.05. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific has a 52 week low of $80.64 and a 52 week high of $109.50. The company has a market cap of $144.17 billion, a PE ratio of 57.91, a P/E/G ratio of 2.32 and a beta of 0.61.

Institutional Trading of Boston Scientific

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FWL Investment Management LLC bought a new position in Boston Scientific during the 2nd quarter worth approximately $26,000. Sound Income Strategies LLC raised its position in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after acquiring an additional 120 shares in the last quarter. 1248 Management LLC acquired a new stake in shares of Boston Scientific during the 1st quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new position in Boston Scientific during the first quarter worth $27,000. Finally, Kilter Group LLC acquired a new position in Boston Scientific in the second quarter worth $30,000. 89.07% of the stock is owned by institutional investors.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 174,214 shares of company stock worth $17,972,457 in the last ninety days. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.